COYA THERAPEUTICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.97 USD | -1.32% |
|
-0.33% | -19.43% |
| Jul. 01 | Coya Therapeutics, Inc.(NasdaqCM:COYA) dropped from Russell Microcap Value Index | CI |
| Jul. 01 | Coya Therapeutics, Inc.(NasdaqCM:COYA) dropped from Russell 3000E Value Index | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 12.27 | 106.7 | 90.87 | - | - |
| Enterprise Value (EV) 1 | 12.27 | 106.7 | 90.87 | 90.87 | 90.87 |
| P/E ratio | -1 x | -9.38 x | -5.07 x | -4.34 x | -4.52 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 17.8 x | 18.4 x | 11.3 x | 8.91 x |
| EV / Revenue | - | 17.8 x | 18.4 x | 11.3 x | 8.91 x |
| EV / EBITDA | - | - | -6.44 x | -5.41 x | -4.09 x |
| EV / FCF | - | - | -17.8 x | -5.9 x | -4.25 x |
| FCF Yield | - | - | -5.61% | -16.9% | -23.5% |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 2,590 | 14,401 | 15,221 | - | - |
| Reference price 2 | 4.738 | 7.410 | 5.970 | 5.970 | 5.970 |
| Announcement Date | 3/29/23 | 3/19/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 6 | 4.926 | 8.067 | 10.2 |
| EBITDA 1 | - | - | - | -14.1 | -16.8 | -22.2 |
| EBIT 1 | - | -9.812 | -7.903 | -17.86 | -22.53 | -22.2 |
| Operating Margin | - | - | -131.72% | -362.56% | -279.31% | -217.65% |
| Earnings before Tax (EBT) 1 | - | -12.24 | -7.264 | -17.23 | -22.42 | -22.2 |
| Net income 1 | -4.892 | -12.24 | -7.988 | -17.23 | -22.42 | -22.2 |
| Net margin | - | - | -133.13% | -349.79% | -277.9% | -217.65% |
| EPS 2 | -0.3300 | -4.730 | -0.7900 | -1.177 | -1.377 | -1.320 |
| Free Cash Flow 1 | - | - | - | -5.1 | -15.4 | -21.4 |
| FCF margin | - | - | - | -103.54% | -190.91% | -209.8% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/18/22 | 3/29/23 | 3/19/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 6 | - | 3.85 | - | - | 0.9 | 0.9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -2.9 | -2.904 | -3.564 | 1.815 | - | -2.128 | -6.628 | -7.278 | - | - |
| Operating Margin | - | - | - | 30.25% | - | -55.27% | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -3.095 | -3.422 | 1.99 | - | -2.02 | -6.51 | -7.178 | - | - |
| Net income 1 | -2.736 | -3.095 | -3.422 | 1.266 | -5.052 | -2.02 | -6.51 | -7.178 | - | - |
| Net margin | - | - | - | 21.1% | - | -52.47% | - | - | - | - |
| EPS 2 | -0.2800 | -0.3100 | -0.3400 | 0.1500 | -0.3500 | -0.1400 | -0.4300 | -0.4700 | -0.3400 | -0.3200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 5/10/23 | 8/8/23 | 11/8/23 | 3/19/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -5.1 | -15.4 | -21.4 |
| ROE (net income / shareholders' equity) | - | - | - | -33% | -61% | -248% |
| ROA (Net income/ Total Assets) | - | - | - | -30% | -53% | -190% |
| Assets 1 | - | - | - | 57.43 | 42.3 | 11.68 |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 11/18/22 | 3/29/23 | 3/19/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.97
USD
Average target price
14.83
USD
Spread / Average Target
+148.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.43% | 90.87M | |
| +16.59% | 44.44B | |
| +41.02% | 39.84B | |
| -10.62% | 37.68B | |
| +29.92% | 31.46B | |
| -9.23% | 27.02B | |
| +12.34% | 26.29B | |
| +41.53% | 13.8B | |
| +31.49% | 12.46B | |
| -7.40% | 11.26B |
- Stock Market
- Equities
- COYA Stock
- Financials Coya Therapeutics, Inc.
